GlassScriptPhysician profile
Salgram Jaisinghani
NPI 1265544878
$895.28
in general payments reported to CMS, 2019-2025
21 companies · $448 in 2025
The $448 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $213 · 2022: $190 · 2024: $43.61 · 2025: $448.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $491.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $154.18 | 2025 | Jynarque |
| Takeda Pharmaceuticals U.S.A., INC. | $109.39 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $98.08 | 2025 | Farxiga |
| Novo Nordisk INC | $58.08 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $49.63 | 2024-2025 | Tarpeyo |
| Janssen Pharmaceuticals, INC | $43.72 | 2022 | |
| Scpharmaceuticals INC. | $43.24 | 2025 | |
| Travere Therapeutics, INC. | $39.72 | 2025 | |
| Glaxosmithkline, LLC. | $37.23 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.97 | 2022 | |
| Amgen INC. | $32.62 | 2022-2025 | Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $30.22 | 2021-2022 | |
| Apellis Pharmaceuticals, INC. | $28.49 | 2025 | Empaveli |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.17 | 2024 | Lifevest |
| Pfizer INC. | $26.85 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $19.68 | 2025 | Ibsrela |
| Fresenius USA Marketing, INC. | $14.89 | 2025 | Velphoro |
| Novartis Pharmaceuticals Corporation | $13.18 | 2022 | |
| Abbvie INC. | $12.56 | 2021 | |
| Amarin Pharma, INC. | $12.19 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Salgram Jaisinghani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.